TGNA Stock Overview A biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Transgene Historical stock prices Current Share Price €0.68 52 Week High €1.45 52 Week Low €0.67 Beta 0.85 1 Month Change 2.25% 3 Month Change -24.61% 1 Year Change -43.27% 3 Year Change -69.85% 5 Year Change -52.90% Change since IPO -98.40%
Recent News & Updates Transgene SA to Report First Half, 2025 Results on Sep 16, 2025
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers Oct 14
First half 2024 earnings released: €0.16 loss per share (vs €0.16 loss in 1H 2023) Sep 29
Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments Sep 16
New minor risk - Shareholder dilution Aug 05
Less than half of directors are independent Jul 25 See more updates Transgene SA to Report First Half, 2025 Results on Sep 16, 2025
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers Oct 14
First half 2024 earnings released: €0.16 loss per share (vs €0.16 loss in 1H 2023) Sep 29
Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments Sep 16
New minor risk - Shareholder dilution Aug 05
Less than half of directors are independent Jul 25
New major risk - Financial position May 15
Full year 2023 earnings released: €0.22 loss per share (vs €0.33 loss in FY 2022) Mar 28 Transgene SA Announces Chief Financial Officer Changes Transgene SA to Report Q3, 2024 Results on Nov 07, 2024
First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022) Jan 07
First half 2023 earnings released Sep 21
New major risk - Financial position Jul 03
New minor risk - Share price stability Jun 08
BioInvent Ready for Combination Studies with BT-001 Jun 07
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023 Jun 06
Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023 Jun 05 Transgene SA Appoints Carol Stuckley as Independent Director
Full year 2022 earnings released: €0.33 loss per share (vs €0.21 loss in FY 2021) Mar 18
Transgene Receives Approval to Start a Phase I Trial of TG6050 Jan 06 Transgene SA to Report First Half, 2023 Results on Sep 20, 2023
No longer forecast to breakeven Nov 16
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers Nov 03
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 Sep 12
First half 2022 earnings released Sep 09
Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001 Jun 28
Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022 Jun 06
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022 May 27
Transgene SA Approves Board and Committee Changes May 26
No longer forecast to breakeven Apr 27
Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman Apr 01
No longer forecast to breakeven Mar 17
Transgene to Present New Positive Preliminary Phase I Data on TG4050 Mar 10
Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer Feb 10
Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade Jan 22
Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine Nov 24
First half 2021 earnings released Sep 24
Transgene Announces Update on Phase I Clinical Trial of TG4050 Jun 30
Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers Jun 25
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors Jun 09
Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001 May 27 Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies
Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019) Mar 11
Revenue misses expectations Mar 11
New 90-day high: €2.84 Mar 02
Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors Mar 01
New 90-day high: €2.69 Feb 09
New 90-day high: €2.60 Jan 22
Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy Jan 22
Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors Jan 20
Transgene Appoints Gaëlle Stadtler as Director of Human Resources Jan 15
New 90-day high: €1.74 Jan 07
Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors Dec 21 Transgene SA, Annual General Meeting, May 26, 2021 Transgene Announces Management Changes
First half 2020 earnings released: €0.03 loss per share Nov 21
New 90-day high: €1.57 Nov 11 Transgene SA Announces the Presentation of the Detailed Results from the Phase 1b/2 Trial Combining TG4001, a HPV16-Targeted Therapeutic Vaccine, with Avelumab (BAVENCIO®)
Transgene Announces Detailed Results from the Phase 1B/2 Trial Combining TG4001 Oct 27
Transgene Announces Detailed Results of the Data from the Phase 1b/2 Trial Combining TG4001 Oct 19
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers Oct 06
Transgene SA to Report Fiscal Year 2009 Results on 03/22/2010 Oct 05
First half earnings released Sep 19
New 90-day low - €1.33 Sep 14
A Chinese Investment Fund acquired an unknown minority stake in Shanghai Tasly Pharmaceutical Co., Ltd from Transgene SA (ENXTPA:TNG) for $22.2 million. Aug 06
Vaxxel SAS acquired DuckCelt®-T17 cell line of Transgene SA (ENXTPA:TNG). Jul 31
Mediolanum Farmaceutici S.P.A. acquired ElsaLys Biotech SA. Jul 30 Shareholder Returns TGNA DE Biotechs DE Market 7D 1.9% 1.8% 0.6% 1Y -43.3% -3.9% 13.3%
See full shareholder returns
Return vs Market: TGNA underperformed the German Market which returned 15% over the past year.
Price Volatility Is TGNA's price volatile compared to industry and market? TGNA volatility TGNA Average Weekly Movement 8.0% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: TGNA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TGNA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Show more Transgene SA Fundamentals Summary How do Transgene's earnings and revenue compare to its market cap? TGNA fundamental statistics Market cap €91.47m Earnings (TTM ) -€22.91m Revenue (TTM ) €6.49m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TGNA income statement (TTM ) Revenue €6.49m Cost of Revenue €29.44m Gross Profit -€22.95m Other Expenses -€37.00k Earnings -€22.91m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 27, 2025
Earnings per share (EPS) -0.17 Gross Margin -353.37% Net Profit Margin -352.80% Debt/Equity Ratio -5,956.7%
How did TGNA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/03 06:09 End of Day Share Price 2025/02/03 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Transgene SA is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Olga Smolentseva Bryan Garnier & Co Brandon Folkes Cantor Fitzgerald & Co. Arsene Guekam CIC Market Solutions (ESN)
Show 8 more analysts 
